European journal of cancer & clinical oncology · 1983
An EORTC phase II study of vindesine in advanced prostate cancer.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jones W G, Fosså S D, Denis L, Coninx P, Glashan R W, Akdas A, De Pauw M
Аннотация
In a phase II study of vindesine in patients with bi-dimensionally measurable primary or metastatic prostate cancer, 27 patients (given 3 mg/m2 weekly for at least 4 treatment cycles) were evaluable for response 6 weeks from the start of treatment. Dose escalation to 4 mg/m2 weekly was attempted. Five patients (19%) achieved a partial remission of short duration, 11 patients (41%) showed no change and 11 patients (41%) showed progression. Thirty-one patients were evaluable for toxicity. Neurotoxicity occurred in 58% (severe in 23%) and was apparently cumulative dose-dependent, although there was variable individual sensitivity. Haematological toxicity was evidenced by lack of dose escalation in 32% of patients, dose delay in 71% and some degree of anaemia in 48%. Alopecia occurred in 55%. Other toxicities were few and minor. Vindesine shows marginal activity in prostatic cancer but at this dose schedule causes appreciable toxicity.